Swaraj Suiting seeks approval for ₹174 crore preferential issue
- Swaraj Suiting proposes raising ₹174.20 crore via preferential issue of shares and warrants
- Equity tranche of ₹117.25 crore primarily targets working capital needs
- Warrant tranche of ₹56.95 crore allocates 52.68% to capital expenditure
- Issue price fixed at ₹335 per share/warrant based on NSE VWAP and valuation report

*this image is generated using AI for illustrative purposes only.
Swaraj Suiting Limited has convened an Extraordinary General Meeting (EGM) to seek shareholder approval for a combined capital raise of ₹174.20 crore through the preferential issuance of equity shares and convertible warrants.
The proposal involves issuing up to 35,00,000 equity shares and 17,00,000 warrants, both priced at ₹335 per share or warrant. The funds are earmarked for working capital requirements, general corporate purposes, and capital expenditure initiatives aimed at capacity expansion.
Equity Share Issuance Details
The company plans to allot up to 35,00,000 equity shares with a face value of ₹10 each at a premium of ₹325. This tranche will aggregate to ₹117.25 crore. The allottees include institutional investors such as Clarus Capital I, Kritagyata Trust, and Emerge Capital Opportunities Scheme.
The proceeds from this specific equity issuance will be allocated as follows:
| Purpose | Amount (₹ crore) | % of Issue Size |
|---|---|---|
| Working Capital | 88.25 | 75.26% |
| General Corporate Purposes | 29.00 | 24.74% |
| Total | 117.25 | 100.00% |
Warrant Conversion Plan
Separately, Swaraj Suiting proposes to issue up to 17,00,000 warrants convertible into equal numbers of equity shares. These warrants will also be issued at ₹335 per warrant, aggregating to ₹56.95 crore. The allottees for this tranche include a mix of public entities, trusts, and individual investors such as Anshvardhan Modi and Raghav Agarwal.
The utilization plan for the warrant proceeds is structured to support long-term growth:
| Purpose | Amount (₹ crore) | % of Issue Size |
|---|---|---|
| Capital Expenditure | 30.00 | 52.68% |
| Working Capital | 14.95 | 26.25% |
| General Corporate Purposes | 12.00 | 21.07% |
| Total | 56.95 | 100.00% |
Pricing and Valuation Basis
The issue price of ₹335 was determined based on a valuation report by CA Kapil Dev Dhir, a registered valuer. The floor price was calculated as the higher of the 90-day volume-weighted average price (VWAP) on the National Stock Exchange (NSE) preceding the relevant date of September 24, 2026, which stood at ₹330.04, or the 10-day VWAP of ₹289.64.
The valuation report employed a weighted average method combining Net Asset Value (NAV), Market Price, and Discounted Cash Flow (DCF) methods. The market price method carried the highest weight at 75%, resulting in a weighted average equity share price of ₹292.48. However, regulatory compliance under SEBI ICDR Regulations mandated the floor price of ₹330.04, leading to the final issue price of ₹335.
What the Numbers Show
The dual-instrument approach reveals a strategic balance between immediate liquidity and long-term asset creation. While the equity share issuance is heavily skewed toward working capital (75%), the warrant tranche allocates more than half its proceeds (52.68%) to capital expenditure. This divergence suggests that management intends to use immediate cash from equity sales to sustain operations while leveraging the delayed conversion timeline of warrants to fund manufacturing expansion over the next three years. Notably, Clarus Capital I emerges as a significant stakeholder, holding 9.55% post-equity allotment and adding further exposure through warrants.
Historical Stock Returns for Swaraj Suiting
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.50% | +22.09% | +2.35% | +38.99% | +130.06% | +604.89% |
How will the specific capacity expansion projects funded by the warrant proceeds impact Swaraj Suiting's production margins and competitive positioning in the textile sector?
What are the potential dilution effects on existing shareholders' equity and voting power once the 17,00,000 convertible warrants are fully exercised?
Given Clarus Capital I's significant post-allotment stake, what strategic synergies or board-level influences might this institutional investor introduce to the company?






























